Multifunctional nanoagent for thrombus-targeted fibrinolytic therapy

Nanomedicine

Volumn 7, Issue 7, 2012, Pages 1017-1028

  McCarthy, Jason R ^a   Sazonova, Irina Y ^b   Erdem, S Sibel ^a   Hara, Tetsuya ^a   Thompson, Brian D ^a   Patel, Purvish ^a   Botnaru, Ion ^a   Lin, Charles P ^a   Reed, Guy L ^c   Weissleder, Ralph ^a   Jaffer, Farouc A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

fibrinolytic; imaging; iron oxide; multimodal; theranostic; therapy; thrombosis

Indexed keywords

ALTEPLASE; BLOOD CLOTTING FACTOR 13; DEXTRAN; FIBRINOLYTIC AGENT; IRON OXIDE; NANOPARTICLE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY THROMBOSIS; ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; DRUG PURIFICATION; DRUG SYNTHESIS; ENZYME ACTIVITY; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG EMBOLISM; MOUSE; NONHUMAN; PARTICLE SIZE; PREDICTIVE VALUE; PRIORITY JOURNAL; VEIN THROMBOSIS;

ANIMALS; DEXTRANS; DRUG DELIVERY SYSTEMS; FEMALE; FERRIC COMPOUNDS; HUMANS; LUNG; MICE; MICE, INBRED C57BL; NANOPARTICLES; PLASMINOGEN ACTIVATORS; PULMONARY ARTERY; PULMONARY EMBOLISM; RECOMBINANT PROTEINS; THROMBOLYTIC THERAPY; THROMBOSIS; VEINS; VENOUS THROMBOSIS;

EID: 84864421188     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.11.179     Document Type: Article

References (30)

1. Anderson HV, Willerson JT. Thrombolysis in acute myocardial infarction. N. Engl. J. Med. 329, 703-709 (1993). (Pubitemid 23252265)
2. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. 333, 1581-1587 (1995).
3. Armstrong PW, Collen D. Fibrinolysis for acute myocardial infarction: current status and new horizons for pharmacological reperfusion, part 1. Circulation 103, 2862-2866 (2001). (Pubitemid 32550078)
4. Marsh JN, Hu G, Scott MJ et al. A fbrin-specifc thrombolytic nanomedicine approach to acute ischemic stroke. Nanomedicine (Lond). 6, 605-615 (2011).
5. Bi F, Zhang J, Su Y, Tang YC, Liu JN. Chemical conjugation of urokinase to magnetic nanoparticles for targeted thrombolysis. Biomaterials 30, 5125-5130 (2009).
6. Ma YH, Wu SY, Wu T, Chang YJ, Hua MY, Chen JP. Magnetically targeted thrombolysis with recombinant tissue plasminogen activator bound to polyacrylic acid-coated nanoparticles. Biomaterials 30, 3343-3351 (2009).
7. Marsh JN, Senpan A, Hu G et al. Fibrin-targeted perfuorocarbon nanoparticles for targeted thrombolysis. Nanomedicine 2, 533-543 (2007). (Pubitemid 47365128)
8. Silva GA. Nanotechnology approaches to crossing the blood-brain barrier and drug delivery to the CNS. BMC Neurosci. 9(Suppl. 3), S4 (2008).
9. Ross AM. New plasminogen activators: a clinical review. Clin. Cardiol. 22, 165-171 (1999). (Pubitemid 29116164)
10. McCarthy JR, Patel P, Botnaru I, Haghayeghi P, Weissleder R, Jaffer FA. Multimodal nanoagents for the detection of intravascular thrombi. Bioconjug. Chem. 20, 1251-1255 (2009).
11. Robinson BR, Houng AK, Reed GL. Catalytic life of activated factor XIII in thrombi. Implications for fbrinolytic resistance and thrombus aging. Circulation 102, 1151-1157 (2000).
12. Jaffer FA, Tung CH, Wykrzykowska JJ et al. Molecular imaging of factor XIIIa activity in thrombosis using a novel, near-infrared fuorescent contrast agent that covalently links to thrombi. Circulation 110, 170-176 (2004). (Pubitemid 38924585)
13. Tung CH, Ho NH, Zeng Q et al. Novel factor XIII probes for blood coagulation imaging. Chembiochem 4, 897-899 (2003). (Pubitemid 37185704)
14. Miserus RJ, Herias M V, Prinzen L et al. Molecular MRI of early thrombus formation using a bimodal alpha2-antiplasmin-based contrast agent. JACC Cardiovasc. Imaging 2, 987-996 (2009).
15. Josephson L, Tung CH, Moore A, Weissleder R. High-effciency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjug. Chem. 10, 186-191 (1999). (Pubitemid 29147720)
16. Perez JM, O'Loughin T, Simeone FJ, Weissleder R, Josephson L. DNA-based magnetic nanoparticle assembly acts as a magnetic relaxation nanoswitch allowing screening of DNA-cleaving agents. J. Am. Chem. Soc. 124, 2856-2857 (2002). (Pubitemid 34249946)
17. Zuckermann R, Corey D, Schultz P. Effcient methods for attachment of thiol specifc probes to the 3'-ends of synthetic oligodeoxyribo nucleotides. Nucleic Acids Res. 15, 5305-5321 (1987).
18. Machado LS, Sazonova IY, Kozak A et al. Minocycline and tissue-type plasminogen activator for stroke: assessment of interaction potential. Stroke 40, 3028-3033 (2009).
19. Veilleux I, Spencer JA, Biss DP, Cote D, Lin CP. Cell tracking with video rate multimodality laser scanning microscopy. IEEE J. Selected Topics Quantum Electron. 14, 10-18 (2008). (Pubitemid 351270759)
20. Chang K, Francis SA, Aikawa E et al. Pioglitazone suppresses infammation in vivo in murine carotid atherosclerosis: novel detection by dual-target fuorescence molecular imaging. Arterioscler. Thromb. Vasc. Biol. 30, 1933-1939 (2010).
21. Fraker PJ, Speck JCJ. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem. Biophys. Res. Commun. 80, 849-857 (1978). (Pubitemid 8305904)
22. Sazonova IY, McNamee RA, Houng AK, King SM, Hedstrom L, Reed GL. Reprogrammed streptokinases develop fbrin-targeting and dissolve blood clots with more potency than tissue plasminogen activator. J. Thromb. Haemost. 7, 1321-1328 (2009).
23. Colucci M, Scopece S, Gelato AV, Dimonte D, Semeraro N. In vitro clot lysis as a potential indicator of thrombus resistance to fbrinolysis-study in healthy subjects and correlation with blood fbrinolytic parameters. Thromb. Haemost. 77, 725-729 (1997). (Pubitemid 27182971)
24. Turner RB, Liu L, Sazonova IY, Reed GL. Structural elements that govern the substrate specifcity of the clot-dissolving enzyme plasmin. J. Biol. Chem. 277, 33068-33074 (2002). (Pubitemid 34984822)
25. Korninger C, Collen D. Studies on the specifc fbrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb. Haemost. 46, 561-565 (1981). (Pubitemid 11049531)
26. Lijnen HR, van Hoef B, Beelen V, Collen D. Characterization of the murine plasma fbrinolytic system. Eur. J. Biochem. 224, 863-871 (1994). (Pubitemid 24288847)
27. Diamond SL, Anand S. Inner clot diffusion and permeation during fbrinolysis. Biophys. J. 65, 2622-2643 (1993). (Pubitemid 24005994)
28. Francis CW, Marder VJ. A molecular model of plasmic degradation of crosslinked fbrin. Semin. Thromb. Hemost. 8, 25-35 (1982). (Pubitemid 12148545)
29. Veklich Y, Francis CW, White J, Weisel JW. Structural studies of fbrinolysis by electron microscopy. Blood 92, 4721-4729 (1998). (Pubitemid 29005874)
30. Runge MS, Bode C, Matsueda GR, Haber E. Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo. Proc. Natl Acad. Sci. USA 84, 7659-7662 (1987).